ZymoGenetics

Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Wednesday, August 9, 2023
Amgen, DNA, ZymoGenetics, AACR, Drug development, Therapy, DDR, Neoplasm, Uterine serous carcinoma, Paclitaxel, American Association for Cancer Research, Coronavirus Scientific Advisory Board, Woman, Outer ring road, Medication, Cyclin E1, Biomarker, Bayer, USC, Carboplatin, Carcinoma, MD Anderson Cancer Center, ASCO, Development, State Administrative Expenses, American Society of Clinical Oncology, Patient, Homologous recombination, SAN, University, Administration, Annual general meeting, Cancer, Clinical Ovarian Cancer & Other Gynecologic Malignancies, R, Research, Ovarian cancer, Society, ORR, Safety, Pharmaceutical industry, Cryptocurrency, Cyclin

NEW YORK and SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended June 30, 2023, and highlighted recent corporate accomplishments.

Key Points: 
  • Azenosertib plus chemotherapy combinations also demonstrated positive results in women facing heavily pretreated ovarian cancer.
  • Presented positive azenosertib + chemotherapy combination data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Zentalis is preparing for a Phase 3 trial of azenosertib using intermittent dosing in combination with chemotherapy in Cyclin E1+ platinum-sensitive ovarian cancer.
  • Cash and Marketable Securities Position: As of June 30, 2023, Zentalis had cash, cash equivalents and marketable securities of $553.0 million.

OmniAb Announces the Passing of Director Sunil Patel

Retrieved on: 
Monday, August 7, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, ZymoGenetics, University, OncoMed, Berkeley, Marketing, Sunil, McKinsey & Company, Chemistry, Investment, Gilead Sciences, University of Washington Department of Bioengineering, Pleasure, Chairperson, Connetable (Gatchina), Ligand Pharmaceuticals, Management

OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week.
  • The Board of Directors and leadership of OmniAb extend their deepest condolences to those who loved and cared for Sunil and express their gratitude for Sunil’s many contributions to OmniAb.
  • “It is with profound sadness that we announce Sunil’s passing,” said John Higgins, OmniAb Board Chair.
  • “Sunil was a highly-valued and engaged member of the OmniAb Board of Directors and played an important role driving our investments and strategy.

Korro Strengthens Leadership Team with Appointment of Shelby Walker as General Counsel

Retrieved on: 
Wednesday, May 10, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, University of New Hampshire School of Law, Intellectual property, ZymoGenetics, CRISPR, University, Worcester Polytechnic Institute, Therapy, General counsel, Bio, LLM, Corporate governance, MBA, RNA, Associate, Ginkgo Bioworks, Johns Hopkins University, JD, Novo Nordisk, CRISPR Therapeutics, Shelby Walker, RNA editing, Pharmaceutical industry, Management

Korro Bio, a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Shelby Walker, JD, as Senior Vice President and General Counsel.

Key Points: 
  • Korro Bio, a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Shelby Walker, JD, as Senior Vice President and General Counsel.
  • In this new role, Ms. Walker will lead Korro’s legal organization including Intellectual Property, Corporate Governance and Compliance functions.
  • “It gives me great pleasure to welcome Shelby to Korro.
  • Prior to this role, she served as General Counsel at Ginkgo Bioworks and as Vice President, Associate General Counsel and Chief IP Counsel at Dyax Corporation.

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Wednesday, May 10, 2023
ZymoGenetics, G&A, Development, Gene amplification, Patient, Roche, R, Amgen, Therapy, American Board of Obstetrics and Gynecology, Coronavirus Scientific Advisory Board, Bayer, WEE1, CCNE1, AACR, Cancer, American Association for Cancer Research, BRAF, Cyclin E1, Biomarker, Acute myeloid leukemia, MD Anderson Cancer Center, AL, Administration, SAN, University, Amyloidosis, Research, Ovarian cancer, Partnership, Drug development, Clinical trial, Pfizer, Medication, Cetuximab, Trial of the century, ASCO, State Administrative Expenses, AML, Foundation Medicine, Pharmaceutical industry, Medical device, Cyclin

“I share Zentalis’ passion and commitment to developing therapeutics for difficult-to-treat cancers,” said Dr. Hausman.

Key Points: 
  • “I share Zentalis’ passion and commitment to developing therapeutics for difficult-to-treat cancers,” said Dr. Hausman.
  • The Company remains on track to provide an update on azenosertib monotherapy dosing in the first half of 2023.
  • Cash and Marketable Securities Position: As of March 31, 2023, Zentalis had cash, cash equivalents and marketable securities of $392 million.
  • General and Administrative Expenses: General and administrative (G&A) expenses for the quarter ended March 31, 2023 were $16.4 million, compared to $11.8 million during the three months ended March 31, 2022.

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

Retrieved on: 
Monday, April 10, 2023
Amgen, ZymoGenetics, Biotechnology, Drug development, Executive, Senior, University, Seagen, Biogen, Binghamton University, University School, State university system, Drug, Janssen, Massachusetts General Hospital, Buffalo, Bristol Myers Squibb, Canagliflozin, Biology, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Merck & Co., Organization, Research and development, Development, Patient, New York University Grossman School of Medicine, Robert Wood Johnson University Hospital, Internal medicine, University of Massachusetts Lowell, IND World's Fair Line, Genetic, Hospital, SANA, IND, Research and Development Council of New Jersey, Management, Pharmaceutical industry, Vertex, Endocrinology, Merck, Research

SEATTLE, April 10, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointments of two senior leaders to its research and development organization, Douglas E. Williams, Ph.D., as President of Research and Development, and Gary Meininger, M.D., as Chief Medical Officer. In a planned transition, Sunil Agarwal, M.D., Chief Medical Officer, will leave the company after helping onboard these new executives.

Key Points: 
  • In a planned transition, Sunil Agarwal, M.D., Chief Medical Officer, will leave the company after helping onboard these new executives.
  • In his career, he has participated in the development of over a dozen approved medicines across multiple therapeutic areas, including multiple blockbusters.
  • Dr. Meininger has over two decades of experience in drug development leadership, most recently at Vertex and previously at both Janssen and Merck.
  • He is currently the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee.

EMulate Therapeutics Announces the Addition of Donna Morgan Murray, Ph.D., to its Board of Directors

Retrieved on: 
Tuesday, March 14, 2023
Acquisition, University, Therapy, Emulate, Glioblastoma, Biomedical sciences, BMY, Knowledge, ZymoGenetics, Publication, Cancer, Patent, Bristol Myers Squibb, Doctor of Philosophy, Chronic pain, Gannon University, GBM, Pharmaceutical industry, Biology, Immunology

“Donna is an experienced leader who brings more than three decades of expertise from across the biotech sector to EMulate’s strategic leadership.

Key Points: 
  • “Donna is an experienced leader who brings more than three decades of expertise from across the biotech sector to EMulate’s strategic leadership.
  • Prior to becoming the chief regulatory officer for EMulate, Dr. Murray held several leadership positions at Bristol-Myers Squibb including head of global quality and regulatory compliance.
  • Before her tenure at BMY, Dr. Murray also spent time in regulatory leadership roles at CuraGen Corporation and Proctor and Gamble Pharmaceuticals.
  • Dr. Murray holds a Ph.D., in Immunology from the University of Texas Graduate School of Biomedical Sciences and a B.S.

Stablix Appoints Douglas Williams, Ph.D., to Board of Directors

Retrieved on: 
Wednesday, January 18, 2023
Dimethyl fumarate, Development, Biotechnology, Senior, Biogen, Biology, Research and development, Protein, Seagen, Amgen, Drug discovery, TPS, Etanercept, ZymoGenetics, Bristol Myers Squibb, Management, Research

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced the appointment of Douglas E. Williams, Ph.D. to its Board of Directors.

Key Points: 
  • NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced the appointment of Douglas E. Williams, Ph.D. to its Board of Directors.
  • “We’re very pleased to welcome Doug to the Stablix Board,” said Tony Kingsley, Stablix CEO.
  • He joined Biogen from ZymoGenetics, where he was most recently CEO and member of the Board of Directors.
  • He has served on the board of numerous biotechnology companies and is currently Chairman of the Board of AC Immune, and is a Director for Panacea II.

CDR-Life Announces the Appointment of Nicole Onetto, MD, MSc, to Board of Directors

Retrieved on: 
Thursday, December 8, 2022
Roche, Breast cancer, ImmunoGen, Pediatrics, Master of Science, Acquisition, BMS, OSI Pharmaceuticals, Partnership, Bristol Myers Squibb, Ovarian cancer, YM Biosciences, Safety, University, Cancer, Biotechnology, ZymoGenetics, Ontario Institute for Cancer Research, Doctor of Philosophy, Genentech, MD, Geographic atrophy, MHC, Drug development, Severe cognitive impairment, Therapy, Gilead Sciences, Boehringer Ingelheim, Hematology, Senior, Patient, Fine chemical, Pharmaceutical industry, Medicine, Paclitaxel, Pharmacology

We are very pleased to welcome Dr. Nicole Onetto to our Board.

Key Points: 
  • We are very pleased to welcome Dr. Nicole Onetto to our Board.
  • Dr. Onetto previously worked in senior management positions at Bristol Myers Squibb (BMS), Nexstar Pharmaceuticals, and Gilead Sciences.
  • Dr. Onetto holds a medical degree from the University of Paris and a Master of Pharmacology from the University of Montréal.
  • CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide.

GNS Appoints John Maraganore as Chair of the Board

Retrieved on: 
Thursday, November 3, 2022
Board, Chicago (franchise), RNA interference, Takeda Oncology, Patient, Chairperson, HIV disease progression rates, Investment, Neurology, Norwest Venture Partners, Agios Pharmaceuticals, University, Neurodegeneration, Molecular biology, GNS, Social media, Upjohn, Senior advisor, AI, M&A, Growth, Biogen, BIO, Biotechnology Innovation Organization, CEO, Advisory board, Research, Leadership, Digital twin, ZymoGenetics, RNA, Atlas Venture, Takeda Pharmaceutical Company, Industry, Nucleation, Therapy, Director, Partner, Business, The Advisory Board Company, Degenerative disease, Biochemistry, Pharmaceutical industry, Alnylam Pharmaceuticals, Inclisiran

Maraganore, who became a strategic advisor to GNS in June 2022 succeeds Timothy Thompson, who served as Executive Chair since 2020.

Key Points: 
  • Maraganore, who became a strategic advisor to GNS in June 2022 succeeds Timothy Thompson, who served as Executive Chair since 2020.
  • From his roles at Biogen to Millennium Pharmaceuticals to Alnylam, John is the rare individual who has brought innovation to market.
  • "I would like also to thank our outgoing Board Chair, Timothy Thompson, who will remain on the board, for his dedication and valuable service to GNS."
  • Dr. Maraganore is Chair Emeritus and a member of the Board of the Biotechnology Innovation Organization (BIO), where he was Chair from 2017-2019.

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Safety, Upjohn, RNA interference, Alnylam Pharmaceuticals, Patient, Chicago (franchise), U.S. Securities and Exchange Commission, Therapeutic index, Leadership, NASDAQ, Research, International law, Atlas Venture, Time, Cytokine, COVID-19, Orbital, Investment, Johnson & Johnson, Biochemistry, Tumor microenvironment, SEC, Takeda Oncology, Patent, Molecular biology, J&J, Atlas, Master of Laws, Agios Pharmaceuticals, Goal, Janssen, GLOBE, Biotechnology Innovation Organization, Immune system, Biogen, GPS, Therapy, Twitter, University of Antwerp, LinkedIn, Private Securities Litigation Reform Act, Cancer, Ortho Pharmaceutical, RNA, Biotechnology, R, University, Pharmaceutical industry, Management, ZymoGenetics, MorphoSys

WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the companys board of directors.

Key Points: 
  • WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the companys board of directors.
  • The collective experience of Tom and John will be highly valuable as Xilio continues to advance its innovative scientific platform and promising pipeline of tumor-selective immunotherapy programs, said Paul Clancy, chair of the board of directors of Xilio Therapeutics.
  • Mr. Heyman currently serves as a member of the boards of directors of Legend Biotech, Akero Therapeutics, OptiNose, and Adagio Therapeutics.
  • He is chair of the board of directors of Hemab Therapeutics and the chairman and co-founder of Orbital Therapeutics.